Steve E. Krognes Denali Therapeutics Inc. (DNLI) insider trading activity

DNLI Quotes by TradingView

Steve E. Krognes is Director of Denali Therapeutics Inc.. Currently has a direct ownership of 29,096 shares of DNLI, which is worth approximately $624,109. The most recent transaction as insider was on Sep 30, 2024, when has been sold 30,000 shares (Common Stock) at a price of $29.03 per share, resulting in proceeds of $870,900. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 29.1K
10.96% 3M change
80.04% 12M change
Total Value Held $624,109

Steve E. Krognes Transaction History

Date Transaction Value Shares Traded Shares Held Form
Sep 30 2024
SELL
Open market or private sale
$870,900 $29.03 p/Share
30,000 Reduced 50.76%
29,096 Common Stock
Aug 20 2024
SELL
Open market or private sale
$41,085 $23.79 p/Share
1,727 Reduced 5.02%
32,677 Common Stock
Jul 01 2024
SELL
Open market or private sale
$673,800 $22.46 p/Share
30,000 Reduced 46.58%
34,404 Common Stock
Jun 13 2024
SELL
Open market or private sale
$14,991 $21.79 p/Share
688 Reduced 1.29%
52,620 Common Stock
May 31 2024
BUY
Grant, award, or other acquisition
-
5,967 Added 10.07%
53,308 Common Stock
Apr 01 2024
SELL
Open market or private sale
$1,896,250 $20.5 p/Share
92,500 Reduced 66.15%
47,341 Common Stock
Feb 13 2024
SELL
Open market or private sale
$47,547 $17.29 p/Share
2,750 Reduced 1.93%
139,841 Common Stock
Jan 05 2024
SELL
Open market or private sale
$62,331 $19.43 p/Share
3,208 Reduced 2.2%
142,591 Common Stock
Aug 21 2023
SELL
Open market or private sale
$32,069 $22.6 p/Share
1,419 Reduced 0.96%
145,799 Common Stock
Jun 01 2023
BUY
Grant, award, or other acquisition
-
4,216 Added 2.78%
147,218 Common Stock
Feb 13 2023
SELL
Open market or private sale
$63,781 $30.1 p/Share
2,119 Reduced 1.46%
143,002 Common Stock
Feb 08 2023
SELL
Open market or private sale
$42,521 $30.88 p/Share
1,377 Reduced 0.94%
145,121 Common Stock
Jan 05 2023
SELL
Open market or private sale
$84,466 $28.44 p/Share
2,970 Reduced 1.99%
146,498 Common Stock
Aug 19 2022
SELL
Open market or private sale
$74,845 $33.22 p/Share
2,253 Reduced 1.48%
149,468 Common Stock
Jul 19 2022
BUY
Exercise of conversion of derivative security
$42,500 $0.68 p/Share
62,500 Added 29.18%
151,721 Common Stock
Feb 11 2022
SELL
Open market or private sale
$88,806 $34.69 p/Share
2,560 Reduced 2.09%
120,221 Common Stock
Feb 09 2022
SELL
Open market or private sale
$48,069 $37.09 p/Share
1,296 Reduced 1.04%
122,781 Common Stock
Jan 05 2022
SELL
Open market or private sale
$99,569 $44.75 p/Share
2,225 Reduced 1.76%
124,077 Common Stock
Jan 03 2022
BUY
Grant, award, or other acquisition
-
31,000 Added 19.71%
126,302 Common Stock
Aug 19 2021
SELL
Open market or private sale
$113,793 $49.8 p/Share
2,285 Reduced 2.34%
95,302 Common Stock
Feb 11 2021
SELL
Open market or private sale
$214,878 $70.8 p/Share
3,035 Reduced 3.02%
97,587 Common Stock
Feb 09 2021
SELL
Open market or private sale
$108,426 $74.88 p/Share
1,448 Reduced 10.04%
12,979 Common Stock
Feb 07 2021
BUY
Exercise of conversion of derivative security
-
4,250 Added 22.76%
14,427 Common Stock

Also insider at

GRTS
Gritstone bio, Inc. Healthcare
Director
GH
Guardant Health, Inc. Healthcare
Director
PLRX
PLIANT THERAPEUTICS, INC. Healthcare
Director
SEK

Steve E. Krognes

Director
South San Francisco, CA

Track Institutional and Insider Activities on DNLI

Follow Denali Therapeutics Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells DNLI shares.

Notify only if

Insider Trading

Get notified when an Denali Therapeutics Inc. insider buys or sells DNLI shares.

Notify only if

News

Receive news related to Denali Therapeutics Inc.

Choose your preferred platform and Sign Up 👇 Telegram Email
Track Activities on DNLI